S
Sonia Morè
Publications - 21
Citations - 89
Sonia Morè is an academic researcher. The author has contributed to research in topics: Medicine & Multiple myeloma. The author has an hindex of 3, co-authored 6 publications receiving 19 citations.
Papers
More filters
Journal ArticleDOI
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
Massimo Offidani,Laura Corvatta,Sonia Morè,Davide Nappi,Giovanni Martinelli,Attilio Olivieri,Claudio Cerchione +6 more
TL;DR: Daratumumab exerts anti-myeloma activity by different mechanisms of action as antibodydependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxin (CDC), direct apoptosis, and immunomodulation as discussed by the authors.
Journal ArticleDOI
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
TL;DR: The first-in-class monoclonal antibody-drug conjugate (ADC) was proposed in this paper to induce an effective and durable response in triple-class refractory disease.
Journal ArticleDOI
Novel Experimental Drugs for Treatment of Multiple Myeloma.
TL;DR: In this paper, the authors reviewed targeted drugs to understand what the best therapeutic strategy in multiple myeloma (MM) is, and reported the results of these new therapies and explored their potential applications.
Journal ArticleDOI
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
L. Bertamini,Stefania Oliva,Delia Rota Scalabrini,Laura Paris,Sonia Morè,Paolo Corradini,Antonio Ledda,Massimo Gentile,Giovanni De Sabbata,Giuseppe Pietrantuono,Anna Pascarella,Patrizia Tosi,Paola Curci,Milena Gilestro,Andrea Capra,Piero Galieni,Francesco Pisani,Ombretta Annibali,Federico Monaco,Anna Marina Liberati,Salvatore Palmieri,Mario Luppi,Renato Zambello,Francesca Fazio,Angelo Belotti,Paola Tacchetti,Pellegrino Musto,Mario Boccadoro,Francesca Gay +28 more
TL;DR: In multiple myeloma, increasing levels of CTC above an optimal cutoff represent an easy-to-assess, robust, and independent high-risk factor.
Journal ArticleDOI
Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment.
Sonia Morè,Maria Teresa Petrucci,Laura Corvatta,Francesca Fazio,Massimo Offidani,Attilio Olivieri +5 more
TL;DR: The results of major clinical studies that have been conducted with elotuzumab, daratumumab and isatuximab in RRMM are described and the emerging MoAbs-based combinations in the RRMM landscape are summarized.